Key clinical point: Deuterated ruxolitinib slowed hair loss and increased hair growth in patients with moderate-severe alopecia areata.
Major finding: The 8 mg twice daily dose decreased hair loss by at least 50% in 47% of patients.
Study details: The dose-finding, placebo-controlled study enrolled 101 patients with moderate to severe alopecia areata.
Disclosures: Dr. Cassella is the chief development officer of Concert Pharmaceuticals, the company developing the molecule.
Cassella, James et al. AAD 2019, S034, late breaking clinical trials.